Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/-bolus therapy for Type 1 diabetes in a UK setting. An economic evaluation based on a meta-analysis of four clinical trials

被引：0

作者：

Roze, S

Palmer, AJ

Valentine, WJ

Smith, IC

Wittrup-Jensen, K

机构：

[1] CORE, Ctr Outcomes Res, Dept Stat, Binningen, Switzerland

[2] CORE, Ctr Outcomes Res, Dept Hlth Econ & Modelling, Binningen, Switzerland

[3] CORE, Ctr Outcomes Res, Dept Med Writing, Binningen, Switzerland

[4] Novo Nordisk Ltd UK, Regulatory Dept, Crawley, England

[5] Novo Nordisk AS, Global Dev Hlth Econ & Outcomes Res, DK-2880 Bagsvaerd, Denmark

来源：

DIABETOLOGIA | 2004年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

960

引用

页码：A345 / A345

页数：1

共 39 条

[1] Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
Palmer, AJ
Roze, S
Valentine, WJ
Smith, I
Wittrup-Jensen, KU
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (11) : 1729 - 1746
[2] Economic evaluation of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting
Tucker, DM
Wittrup-Jensen, KU
Roze, S
Valentine, WJ
Palmer, AJ
[J]. DIABETES, 2005, 54 : A609 - A609
[3] Economic evaluation of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type-1 diabetes in Germany
Palmer, AJ
Valentine, WJ
Wittrup-Jensen, KU
Roze, S
[J]. VALUE IN HEALTH, 2005, 8 (06) : A161 - A161
[4] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
[J]. DIABETOLOGIA, 2007, 50 : S428 - S428
[5] Economic evaluation of detemir-based basal/bolus therapy versus neutral protamine Hagedorn-based basal/bolus therapy for type-1 diabetes in a Dutch setting
Roze, S
Wittrup-Jensen, K
Valentine, WJ
Palmer, AJ
[J]. VALUE IN HEALTH, 2005, 8 (03) : 356 - 356
[6] Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Scheilbeler, H.
Aagren, M.
Nielsen, S.
Goodall, G.
Kotchie, R.
Valentine, W. J.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
[7] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Portugal
Silva, C.
Alves, C.
Negreiro, F.
Fonseca, M. A.
Aagren, M.
[J]. VALUE IN HEALTH, 2008, 11 (03) : A227 - A227
[8] Cost-utility of insulin detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a French setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Schejbeler, H.
Aagren, M.
Nielsen, S.
Valentine, W. J.
Goodall, G.
Kotchie, R.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A268 - A268
[9] Visceral fat mass in patients with Type 2 diabetes is reduced during insulin Detemir-based basal bolus therapy, whereas it is increased during NPH-insulin-based basal bolus therapy
Tinahones, Francisco Jose
Martin, Miguel
Cardona, Fernando
Macias-Gonzalez, Manuel
[J]. OBESITY AND METABOLISM-MILAN, 2008, 4 (03): : 165 - 168
[10] Visceral fat mass in patients with type 2 diabetes is reduced during insulin detemir-based basal bolus therapy, whereas it is increased during NPH-insulin-based basal bolus therapy
Tinahones, Francisco J.
Martin, Miguel
Macias-Gonzalez, Manuel
[J]. DIABETES, 2008, 57 : A167 - A167

← 1 2 3 4 →